GLP1R and hydrops fetalis: AMPLITUDE-O with efpeglenatide, the latest GLP-1 RA CVOT to report (Gerstein et al., 2021), indeed indicated a benefit on HF, with post hoc analyses showing a significant 39% relative risk reduction on HF requiring hospitalisation (HR 0.61; 95%CI 0.38–0.98) (Sattar et al., 2021).